Skip to main content

Table 1 Baseline patient characteristics

From: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study

  Biologic naive (n = 673) Biologic failure (n = 1677)
Age, years 59.9 (12.7) 57.0 (12.5)
Female, n (%) 496 (73.7) 1379 (82.2)
BMI, kg/m2 27.0 (5.4); n = 644 27.1 (5.6); n = 1597
BMI, n (%)
 < 25 kg/m2 265 (41.1) 649 (40.6)
 25–< 30 kg/m2 224 (34.8) 543 (34.0)
 ≥ 30–< 35 kg/m2 104 (16.1) 266 (16.7)
 ≥ 35 kg/m2 51 (7.9) 139 (8.7)
RA duration, years 7.2 (8.2); n = 669 12.1 (9.1); n = 1669
RA duration, n (%)
 ≤ 2 years 239/669 (35.7)* 151/1669 (9.0)
 3–5 years 155/669 (23.2) 320/1669 (19.2)
 6–10 years 122/699 (18.2) 421/1669 (25.2)
 > 10 years 153/699 (22.9) 777/1669 (46.6)
TJC28 9.0 (6.5); n = 633 10.4 (7.2); n = 1599
SJC28 6.6 (5.0); n = 641 7.0 (5.6); n = 1607
DAS28 (ESR)a 5.3 (1.2); n = 582 5.5 (1.3); n = 1422
DAS28 (CRP)a 4.8 (1.1); n = 568 5.0 (1.1); n = 1411
CDAIa 27.5 (11.5); n = 565 30.0 (12.9); n = 1388
SDAIa 29.1 (12.0); n = 526 31.8 (13.6); n = 1279
HAQ-DI 1.4 (0.7); n = 579 1.5 (0.7); n = 1471
PtGA, 100 mm VAS 62.0 (20.3); n = 620 65.4 (19.9); n = 1539
CRP, mg/dL 1.7 (2.6); n = 590 2.1 (3.5); n = 1474**
ESR, mm/h 33.1 (23.7); n = 605 33.7 (23.7); n = 1491
RF positive, n/N (%) 415/578 (71.8) 987/1385 (71.3)
Anti-CCP positive, n/N (%) 368/556 (66.2) 884/1309 (67.5)
RF and anti-CCP antibody status, n/N (%)
 Double positive 311/513 (60.6) 717/1166 (61.5)
 Single positive 77/513 (15.0) 182/1166 (15.6)
 Double negative 125/513 (24.4) 267/1166 (22.9)
Radiographic erosion, n/N (%) 353/607 (58.2) 1034/1446 (71.5)*
≥ 1 Co-morbidity, n (%) 518 (77.0) 1226 (73.1)
 Diabetes mellitus 85 (12.6) 207 (12.3)
 COPD 69 (10.3) 128 (7.6)
 Cardiac disorders 62 (9.2) 124 (7.4)
 Neoplasmsb 36 (5.3) 42 (2.5)*
Number of previous csDMARDsc, n (%)
 ≤ 3 655 (98.8) 1561 (93.1)
 > 3 8 (1.2) 116 (6.9)*
Previous MTX, n (%) 621 (92.3) 1552 (92.5)
Previous other csDMARDs, n (%)
 Leflunomide 278 (41.3) 951 (56.7)*
 Hydroxychloroquine/chloroquine 229 (34.0) 681 (40.6)**
 Sulfasalazine 148 (22.0) 578 (34.5)*
Previous corticosteroids, n (%) 533 (79.2) 1386 (82.6)
Previous other biologics, n (%)
 Adalimumab 967 (57.7)
 Anakinra 69 (4.1)
 Canakinumab 1 (0.1)
 Certolizumab 52 (3.1)
 Etanercept 1010 (60.2)
 Golimumab 22 (1.3)
 Infliximab 512 (30.5)
 Ocrelizumab 3 (0.2)
 Rituximab 239 (14.3)
 Tocilizumab 181 (10.8)
Number of previous biologics, n (%)
 1 728 (43.4)
 ≥ 2 949 (56.6)
Number of previous TNFi, n (%)
 1 872 (52.0)
 ≥ 2 805 (48.0)
Treatment pattern at initiation, n (%)
 Abatacept monotherapy 112 (16.6) 427 (25.5)*
 MTX (± other csDMARDs) 436 (77.7) 947 (75.7)
  MTX alone 358 (63.8) 829 (66.3)
  MTX + other csDMARD 78 (13.9) 118 (9.4)
 Other csDMARDs 125 (22.3) 303 (24.3)
 Corticosteroids 455 (67.6) 1190 (71.0)
  > 5 mg/day 208/440 (47.3) 625/1138 (54.9)**
  ≤ 5 mg/day 232/440 (52.7) 513/1138 (45.1)
  Median dose, mg/day 5.0; n = 440 7.5; n = 1138**
  1. Data are mean (SD) unless indicated otherwise
  2. aCalculated
  3. bBenign, malignant, and unspecified (neoplasms not classified as either benign or malignant). Information on malignancies at baseline was not routinely collected
  4. cMTX and corticosteroids not taken into account
  5. Data in italics indicate a significant difference between biologic-naive and biologic-failure groups (P < 0.05)
  6. *P < 0.001; **P < 0.01
  7. anti-CCP, anti-cyclic citrullinated peptide; BMI, body mass index; CDAI, Clinical Disease Activity Index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; csDMARD, conventional synthetic DMARD; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire–Disability Index; MTX, methotrexate; PtGA, Patient Global Assessment of disease activity; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SDAI, Simplified Disease Activity Index; SJC28, swollen joint count in 28 joints; TJC28, Tender joint count in 28 joints; VAS visual analogue scale